Rx Products (May 2019)

Pharmacy TimesMay 2019 Skin & Eye Health
Volume 85
Issue 5

Marketed by: Shire US Inc

Indication: Xiidra (lifitegrast ophthalmic solution) 5% is a treatment for dry eye, a condition where the eyes are not producing enough moisture that can lead to stinging, burning, itching, irritation, redness, blurred vision, watery eyes, and more. The eye drops were clinically shown to reduce dry eye symptoms after 6 and 12 weeks, with some patients experiencing relief in just 2 weeks, in 4 separate 12-week studies of over 1,000 patients. The eyedrops also reduced symptoms of inferior corneal staining in 3 of the 4 studies.

For more information: Xiidra.com


Manufactured by: CutisPharma

Indication: CutisPharma recently announced the launch of First-Atenolol, a grape flavored oral solution compounding kit to meet the needs of patients who are not currently being served by commercially available therapies, such as those who cannot swallow solid oral formulations. The compounding kit will enable pharmacists to create an oral solution in a convenient, high quality, and standardized way. Atenolol is a beta blocker indicated to treat high blood pressure.

Dosage Form: Oral Solution

For more information: CutisPharma


Manufactured by: Genentech

Indication: Genentech has received accelerated FDA approval for the use of their drug Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound particles for suspension (albumin-bound); nab-paclitaxel]) to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer with a tumor expressing PD-L1. Tecentriq with nab-paclitaxel is the first FDA approved immunotherapy regimen for breast cancer.

Dosage form: Intravenous injection

For more information: Tecentriq.com


Manufactured by: Fera Pharmaceuticals

Indication: The FDA has recently approved Fera Pharmaceuticals for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis. Acyclovir has been successful in treating herpes infections, prompting Fera to manufacture the drug in a ophthalmic dosage form. Avaclyr has been granted orphan drug exclusivity, with seven years of marketing exclusivity for the drug.

Dosage form: ointment

For more information: FeraPharma.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.